Clinical Trial Update: A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating risankizumab in adults and adolescents with moderate to severe atopic dermatitis completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2021-11-18